The companies said that their vaccine was safe and effective in that age group, and that they would submit a formal request in the coming weeks to U.S. regulators to allow a pediatric dose.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.